Norton Rose Fulbright (New York)

Robin Adelstein

Norton Rose Fulbright (New York)
Global Head of Antitrust and Competition and Co-Head of Commercial Litigation

Robin Adelstein joined Norton Rose Fulbright in 2015. She is now Global Head of Antitrust and Competition and Co-Head of Commercial Litigation. Robin Adelstein’s pragmatic approach to the practice of law is informed by her experience, having served as in-house counsel at Swiss healthcare company Novartis and UK alcohol beverage leader Diageo before becoming North American General Counsel of Sandoz, the generics and biosimilars division of Novartis. Whether involving pharmaceuticals, consumer products or other industries, Robin has advised her clients on a wide variety of antitrust issues and directed material litigation and government investigations to positive results. As a former General Counsel of a multibillion-dollar company, Robin knows first-hand the importance of providing prompt, accurate and practical advice on legal and compliance issues, particularly in the context of balancing complex business objectives. Robin also understands the challenges with managing outside counsel, having redesigned and run the Novartis Preferred Firm Program globally.

Distinctions

Linked authors

Norton Rose Fulbright (London)
Norton Rose Fulbright (Paris)
Norton Rose Fulbright (Brussels)
Norton Rose Fulbright (Toronto)
Norton Rose Fulbright (London)

Articles

78 Bulletin

Robin Adelstein, Amanda L. Wait, Richard A. Wagner, Ian Giles, Jay Modrall, Marta Giner Asins The US FTC announces the formation of a working group to examine the US, Canada, UK, and EU agencies’ approach to mergers in the pharmaceutical sector

32

This article has been nominated for the 2022 Antitrust Writing Awards. Click here to learn more about the Antitrust Writing Awards. On March 16, the US Federal Trade Commission, US Department of Justice, offices of US state Attorneys General, the Canadian Competition Bureau, the European (...)

Robin Adelstein, Gerald Stein The US DoJ announces changes to its antitrust compliance program policy which include increased leniency for companies with robust compliance programs

46

This article has been nominated for the 2020 Antitrust Writing Awards. Click here to learn more about the Antitrust Writing Awards. In a historic shift, prosecutors with the US Department of Justice’s (DOJ) antitrust division (the "Division") will now consider providing credit in the charging (...)

8886 Review

Alden F. Abbott, Robin Adelstein, Megan Browdie, Michael A. Carrier, Peter C. Carstensen, Samuel Clark, Lisl J. Dunlop, Harry First, Albert A. Foer, Eleanor M. Fox, Jacqueline Grise, Ryan Kantor, Donald C. Klawiter, John Kwoka, James Langenfeld, Tad Lipsky, Alessandro Massolo, Howard Morse, Gabriella Muscolo, James Bo Pearl, Noah Pinegar, Chris Ring, Christopher Sagers, Richard S. Taffet, Willard K. Tom, Eliot Turner, Doug Tween, Tommaso Valletti, Michael L. Weiner The new US antitrust administration

8886

This Concurrences special set of articles focuses on antitrust law and enforcement in the aftermath of the American Presidential Elections. It questions the changes and challenges expected in 2021 under the new Biden administration, and its impacts with respect to antitrust legislation and (...)

Send a message